Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive breast cancer: editorial commentary.
作者信息
Coleman Robert
机构信息
Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
出版信息
Ann Transl Med. 2024 Aug 1;12(4):60. doi: 10.21037/atm-2023-3. Epub 2023 Mar 17.
Abstract
摘要
相似文献
1
Daily oral ibandronate with adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive breast cancer: editorial commentary.绝经后雌激素受体阳性乳腺癌女性患者每日口服伊班膦酸钠联合辅助内分泌治疗：编辑评论
Ann Transl Med. 2024 Aug 1;12(4):60. doi: 10.21037/atm-2023-3. Epub 2023 Mar 17.
2
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.每日口服伊班膦酸盐联合辅助内分泌治疗绝经后雌激素受体阳性乳腺癌（BOOG 2006-04）：随机 III 期 TEAM-IIB 试验。
J Clin Oncol. 2022 Sep 1;40(25):2934-2945. doi: 10.1200/JCO.21.00311. Epub 2022 Apr 20.
3
Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?内分泌治疗反应性乳腺癌的辅助双膦酸盐：它们在治疗中的地位如何？
Ther Adv Med Oncol. 2009 Nov;1(3):123-36. doi: 10.1177/1758834009344594.
4
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.
5
Potential implications of adjuvant endocrine therapy for the oral health of postmenopausal women with breast cancer.辅助内分泌治疗对乳腺癌绝经后妇女口腔健康的潜在影响。
Breast Cancer Res Treat. 2013 Jan;137(1):23-32. doi: 10.1007/s10549-012-2217-z. Epub 2012 Sep 18.
6
Role of bisphosphonates in postmenopausal women with breast cancer.双膦酸盐类药物在绝经后乳腺癌女性中的作用。
Cancer Treat Rev. 2014 Apr;40(3):476-84. doi: 10.1016/j.ctrv.2013.07.003. Epub 2013 Jul 29.
7
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.三期随机临床试验：双膦酸盐类药物作为乳腺癌辅助治疗：S0307。
J Natl Cancer Inst. 2020 Jul 1;112(7):698-707. doi: 10.1093/jnci/djz215.
8
Bisphosphonates for prevention of postmenopausal osteoporosis.双膦酸盐用于预防绝经后骨质疏松症。
Dan Med Bull. 2002 Feb;49(1):1-18.
9
Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.辅助性他莫昔芬或阿那曲唑治疗后转移性乳腺癌的序贯激素治疗
Breast Cancer Res Treat. 2003;80 Suppl 1:S19-26; discussion S27-8. doi: 10.1023/a:1025459232293.
10
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.绝经后骨质疏松症的每月口服伊班膦酸钠治疗：MOBILE研究的1年结果。
J Bone Miner Res. 2005 Aug;20(8):1315-22. doi: 10.1359/JBMR.050313. Epub 2005 Mar 14.
本文引用的文献
1
Bone-Targeted Agents and Metastasis Prevention.骨靶向药物与转移预防
Cancers (Basel). 2022 Jul 26;14(15):3640. doi: 10.3390/cancers14153640.
2
Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial.每日口服伊班膦酸盐联合辅助内分泌治疗绝经后雌激素受体阳性乳腺癌（BOOG 2006-04）：随机 III 期 TEAM-IIB 试验。
J Clin Oncol. 2022 Sep 1;40(25):2934-2945. doi: 10.1200/JCO.21.00311. Epub 2022 Apr 20.
3
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.辅助双膦酸盐和其他骨修饰剂在乳腺癌中的应用：ASCO-OH（CCO）指南更新。
J Clin Oncol. 2022 Mar 1;40(7):787-800. doi: 10.1200/JCO.21.02647. Epub 2022 Jan 18.
4
Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice.NSABP B-34 研究中早期乳腺癌的扩增和辅助氯膦酸盐的结果及其对临床实践的潜在影响。
JNCI Cancer Spectr. 2021 May 28;5(4). doi: 10.1093/jncics/pkab054. eCollection 2021 Aug.
5
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial.接受 5 年与 2 年辅助双膦酸盐治疗的早期乳腺癌患者的预后：一项 3 期随机临床试验。
JAMA Oncol. 2021 Aug 1;7(8):1149-1157. doi: 10.1001/jamaoncol.2021.1854.
6
Bone metastasis: mechanisms, therapies, and biomarkers.骨转移：机制、疗法和生物标志物。
Physiol Rev. 2021 Jul 1;101(3):797-855. doi: 10.1152/physrev.00012.2019. Epub 2020 Dec 24.
7
Bone health in cancer: ESMO Clinical Practice Guidelines.癌症中的骨骼健康：ESMO临床实践指南
Ann Oncol. 2020 Dec;31(12):1650-1663. doi: 10.1016/j.annonc.2020.07.019. Epub 2020 Aug 12.
8
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.三期随机临床试验：双膦酸盐类药物作为乳腺癌辅助治疗：S0307。
J Natl Cancer Inst. 2020 Jul 1;112(7):698-707. doi: 10.1093/jnci/djz215.
9
Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study.早期乳腺癌患者口服辅助性双膦酸盐的依从性及患者报告的毒性。一项横断面研究。
J Bone Oncol. 2019 Feb 19;15:100226. doi: 10.1016/j.jbo.2019.100226. eCollection 2019 Apr.
10
Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.MAF 扩增对早期乳腺癌辅助唑来膦酸治疗结局的影响：国际、开放标签、随机、对照、III 期 AZURE（BIG 01/04）试验的二次分析。
Lancet Oncol. 2017 Nov;18(11):1543-1552. doi: 10.1016/S1470-2045(17)30603-4. Epub 2017 Oct 13.
Zotero 插件